ALL and Cellular Therapy: Molecular Oncology Tumor Boards

This free case-based activity includes a crowd-sourced discussion of a 23-year-old male with B- lymphoblastic leukemia, BCR-ABL1-like (Ph-like B-ALL) and no significant medical history prior to diagnosis of ALL, and no comorbidities. At diagnosis, cells were positive for CD10, CD19, CD22, CD25, CD34, dim CD45, CD58, TdT, and HLA DR markers; FISH and PCR testing were negative for bcr/abl. Profiling showed Ph-like phenotype and CRLF2 overexpression. Karyotype was 46 XY [20]. Bone marrow biopsy at diagnosis shows B-lymphoblastic leukemia involving 90% of a hypercellular marrow (95% marrow cellularity).

Learning Objectives:

  • Examine the role of CAR T cell therapy for patients with relapsed, refractory ALL
  • Discuss the toxicity and toxicity management after CAR T cell therapy
  • Identify the clinical features and molecular hallmarks of B-lymphoblastic leukemia, BCR-ABL1-like (Ph-like B-ALL)

Continuing Education Credit
1 Credit/Point is available for participation in this course. Certificate and credit types available include:

  • AMA PRA Category 1 Credits™
  • ABIM MOC Points
  • CNE Contact Hours
  • CPE Credits
  • Certificate of Participation may be used to confer credit; however, all final decisions regarding the awarding of credits will be made by the licensing organization to which the credits are submitted.
  • Certificate of Completion may be used to document participation, but no credit will be conferred.

Important Note: This course expires on June 27, 2020. Participants must complete all necessary course components by this date to receive credit